---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059484"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2026-05-12T21:01:51+00:00"
generated_at: "2026-05-12T21:05:02.175927+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# AbbVie shareholders re-elect all Class II directors; reject supermajority elimination and independent chair proposal

## Summary
- All four Class II directors elected: Davis (1.22B for), Meyer (1.28B), Michael (1.22B), Waddell (1.23B).
- Ratification of EY as auditor approved with 1.52B votes for, 23.8M against.
- Advisory say-on-pay approved with 1.23B for, 69.3M against.
- Proposal to eliminate supermajority voting did not pass: 1.29B for (needed supermajority).
- Stockholder proposal for independent chair rejected: 515.6M for, 787.3M against.

## SEC filing metadata
- accession: 0001104659-26-059484
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2026-05-12T21:01:51+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/tm2614276d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059484
- JSON: https://secwatch.observer/filing/0001104659-26-059484.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059484.txt

## Key facts
- Shareholder Votes
  AbbVie Inc. shareholders approved The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026 at the 2026-05-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-05-08
  source text: The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026, as follows: For Against Abstain 1,522,575,012 23,766,564 2,136,457
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm
- Shareholder Votes
  AbbVie Inc. shareholders rejected The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting at the 2026-05-08 meeting.
  - Proposal: charter amendment
  - Outcome: failed
  - Meeting: 2026-05-08
  source text: The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,290,990,023 14,896,119 3,192,310 239,399,581
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm
- Shareholder Votes
  AbbVie Inc. shareholders rejected The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair at the 2026-05-08 meeting.
  - Outcome: failed
  - Meeting: 2026-05-08
  source text: The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows: For Against Abstain Broker Non-Votes 515,626,009 787,253,970 6,198,473 239,399,581
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm
- Shareholder Votes
  AbbVie Inc. shareholders approved The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers at the 2026-05-08 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-05-08
  source text: The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows: For Against Abstain Broker Non-Votes 1,228,615,745 69,336,359 11,126,348 239,399,581
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm
- Shareholder Votes
  AbbVie Inc. shareholders approved The stockholders elected AbbVie’s Class II directors with terms expiring in 2029 at the 2026-05-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-05-08
  source text: The stockholders elected AbbVie’s Class II directors with terms expiring in 2029, as follows: Name For Against Abstain Broker Non-Votes Jennifer L. Davis 1,216,558,754 89,839,329 2,680,369 239,399,581 Melody B. Meyer 1,284,771,578 22,470,074 1,836,800 239,399,581 Robert A. Michael 1,221,224,370 85,865,852 1,988,230 239,399,581 Frederick H. Waddell 1,225,237,825 81,747,033 2,093,594 239,399,581
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.